Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 98 of 2019)
1Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 98 of 2019)
Start here
Get a plain-English read of 1
Turn the raw legal text into a practical explanation grounded in Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 98 of 2019).
Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 98 of 2019)
made under subsection 196B(2) of the
Veterans' Entitlements Act 1986
Compilation No. 2
Compilation date: 22 September 2025
Includes amendments up to: Amendment Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 75 of 2025) (F2025L00977)
About this compilation
This compilation
This is a compilation of the Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 98 of 2019) that shows the text of the law as amended and in force on 22 September 2025.
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Contents
1 Name
3 Authority
5 Application
6 Definitions
7 Kind of injury, disease or death to which this Statement of Principles relates
8 Basis for determining the factors
9 Factors that must exist
10 Relationship to service
11 Factors referring to an injury or disease covered by another Statement of Principles
Section 1 - Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 98 of 2019) - Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 98 of 2019) | Zoe
Schedule 1 - Dictionary
1 Definitions
Endnotes
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Name
This is the Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 98 of 2019).
Authority
This instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.
Application
This instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.
Definitions
The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.
Kind of injury, disease or death to which this Statement of Principles relates
This Statement of Principles is about sensorineural hearing loss and death from sensorineural hearing loss.
Meaning of sensorineural hearing loss
For the purposes of this Statement of Principles, sensorineural hearing loss:
means acquired hearing loss due to a defect in the cochlea or auditory nerve, with a permanent shift to a hearing threshold level of 20 decibels (dB) or more, at 500, 1 000, 1 500, 2 000, 3 000, 4 000 or 6 000 hertz (Hz); and
excludes:
congenital deafness; and
hearing loss due to Meniere disease and Meniere syndrome.
Note: The diagnosis of sensorineural hearing loss is usually made by performing an audiogram in which bone conduction thresholds are measured.
Death from sensorineural hearing loss
For the purposes of this Statement of Principles, sensorineural hearing loss, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's sensorineural hearing loss.
Note: terminal event is defined in the Schedule 1 – Dictionary.
Basis for determining the factors
The Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that sensorineural hearing loss and death from sensorineural hearing loss can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.
Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.
Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting sensorineural hearing loss or death from sensorineural hearing loss with the circumstances of a person's relevant service:
being exposed to a peak sound pressure level at the tympanic membrane of at least 140 dB(C) before the clinical onset of sensorineural hearing loss;
Note: dB(C) is defined in the Schedule 1 - Dictionary.
being exposed to a sound pressure level at the tympanic membrane of at least 85 dB(A) as an 8-hour time-weighted average (TWA) with a 3‑dB exchange rate for a cumulative period of at least six months, before the clinical onset of sensorineural hearing loss;
Note: dB(A) and time-weighted average (TWA) with a 3-dB exchange rate are defined in the Schedule 1 - Dictionary.
being exposed to an explosive blast within the 30 days before the clinical onset of sensorineural hearing loss;
being struck by lightning within the 30 days before the clinical onset of sensorineural hearing loss;
having:
an episode of otitic barotrauma involving the affected ear; or
decompression sickness;
within the 30 days before the clinical onset of sensorineural hearing loss;
undergoing a course of treatment with a drug or a drug from a class of drugs from the specified list of drugs, within the one year before the clinical onset of sensorineural hearing loss;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
having received an ototopical medication as specified, directly into the inner ear, in the presence of tympanic membrane perforation or a patent tympanostomy tube (grommet), within the 30 days before the clinical onset of sensorineural hearing loss;
Note: ototopical medication as specified is defined in the Schedule 1 - Dictionary.
taking paracetamol or a nonsteroidal anti-inflammatory drug on an average of at least two days per week, for a continuous period of at least the one year before the clinical onset of sensorineural hearing loss;
taking a cumulative total of at least 40 grams of aspirin, or having acute salicylate toxicity, within the 30 days before the clinical onset of sensorineural hearing loss;
having a suppurative bacterial infection from the specified list of bacterial infections of the middle or inner ear, involving the affected side, within the 30 days before the clinical onset of sensorineural hearing loss;
Note: specified list of bacterial infections is defined in the Schedule 1 - Dictionary.
having an infection with a virus from the specified list of viruses, within the 30 days before the clinical onset of sensorineural hearing loss;
Note: specified list of viruses is defined in the Schedule 1 - Dictionary.
having viral labyrinthitis of the affected ear within the 30 days before the clinical onset of sensorineural hearing loss;
having meningitis or encephalitis within the one year before the clinical onset of sensorineural hearing loss;
having neurosyphilis before the clinical onset of sensorineural hearing loss;
having tuberculosis of the meninges, middle ear or inner ear of the affected side, before the clinical onset of sensorineural hearing loss;
having leprosy before the clinical onset of sensorineural hearing loss;
having a disease from the specified list of bone diseases, affecting the petrous temporal bone or middle ear ossicles of the affected side, at the time of the clinical onset of sensorineural hearing loss;
Note: specified list of bone diseases is defined in the Schedule 1 - Dictionary.
having osteoporosis at the time of the clinical onset of sensorineural hearing loss;
having a disease from the specified list of autoimmune diseases at the time of the clinical onset of sensorineural hearing loss;
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
having multiple sclerosis at the time of the clinical onset of sensorineural hearing loss;
having diabetes mellitus at the time of the clinical onset of sensorineural hearing loss;
having a disease from the specified list of haematological diseases at the time of the clinical onset of sensorineural hearing loss;
Note: specified list of haematological diseases is defined in the Schedule 1 - Dictionary.
having a cerebrovascular accident within the three months before the clinical onset of sensorineural hearing loss;
having a lesion interrupting the supply of blood to the cochlea of the affected ear at the time of the clinical onset of sensorineural hearing loss;
Note: Examples of lesions interrupting the supply of blood to the cochlea include, but are not limited to, thrombosis, haemorrhage or vasospasm of the vertebro-basilar circulation, and intralabyrinthine haemorrhage or infarction.
having blunt trauma, penetrating trauma or surgery to the cochlea or auditory nerve of the affected side, within the five years before the clinical onset of sensorineural hearing loss;
Note: Examples of trauma include, but are not limited to, temporal bone fracture and basilar skull fracture.
having moderate to severe traumatic brain injury within the three months before the clinical onset of sensorineural hearing loss;
having a benign or malignant neoplasm involving the affected auditory nerve or cochlea at the time of the clinical onset of sensorineural hearing loss;
undergoing a course of therapeutic radiation for cancer, where the affected cochlea or auditory nerve was in the field of radiation, before the clinical onset of sensorineural hearing loss;
inhaling, ingesting or having cutaneous contact with an agent from the specified list of chemical agents, for a cumulative period of at least 2 500 hours within a continuous period of five years, before the clinical onset of sensorineural hearing loss, and where that exposure has ceased, the clinical onset of sensorineural hearing loss has occurred within two years of cessation;
Note: specified list of chemical agents is defined in the Schedule 1 - Dictionary.
having:
a cobalt-containing metal-on-metal hip prosthesis; or
a serum cobalt concentration of at least 200 micrograms per litre;
for at least four weeks before the clinical onset of sensorineural hearing loss;
smoking at least ten pack-years of cigarettes, or the equivalent thereof in other tobacco products, before the clinical onset of sensorineural hearing loss, and where smoking has ceased, the clinical onset of sensorineural hearing loss has occurred within five years of cessation;
Note: pack-years of cigarettes, or the equivalent thereof in other tobacco products is defined in the Schedule 1 - Dictionary.
being exposed to second-hand smoke:
for at least 2 500 hours before the clinical onset of sensorineural hearing loss; and
where the first exposure to second-hand smoke commenced at least five years before the clinical onset of sensorineural hearing loss; and
where the last exposure to second-hand smoke occurred within the two years before the clinical onset of sensorineural hearing loss;
Note: being exposed to second-hand smoke is defined in the Schedule 1 - Dictionary.
consuming an average of at least 100 grams of alcohol per day for at least the four years before the clinical onset of sensorineural hearing loss;
Note: Alcohol consumption is calculated utilising the Australian Standard of ten grams of alcohol per standard alcoholic drink.
being obese for at least five years within the ten years before the clinical onset of sensorineural hearing loss;
Note: being obese is defined in the Schedule 1 - Dictionary.
having hypertension at the time of the clinical onset of sensorineural hearing loss;
being exposed to a peak sound pressure level at the tympanic membrane of at least 140 dB(C) before the clinical worsening of sensorineural hearing loss;
Note: dB(C) is defined in the Schedule 1 - Dictionary.
being exposed to a sound pressure level at the tympanic membrane of at least 85 dB(A) as an 8-hour time-weighted average (TWA) with a 3‑dB exchange rate for a cumulative period of at least six months, before the clinical worsening of sensorineural hearing loss;
Note: dB(A) and time-weighted average (TWA) with a 3-dB exchange rate are defined in the Schedule 1 - Dictionary.
being exposed to an explosive blast within the 30 days before the clinical worsening of sensorineural hearing loss;
being struck by lightning within the 30 days before the clinical worsening of sensorineural hearing loss;
having:
an episode of otitic barotrauma involving the affected ear; or
decompression sickness;
within the 30 days before the clinical worsening of sensorineural hearing loss;
undergoing a course of treatment with a drug or a drug from a class of drugs from the specified list of drugs, within the one year before the clinical worsening of sensorineural hearing loss;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
having received an ototopical medication as specified, directly into the inner ear, in the presence of tympanic membrane perforation or a patent tympanostomy tube (grommet), within the 30 days before the clinical worsening of sensorineural hearing loss;
Note: ototopical medication as specified is defined in the Schedule 1 - Dictionary.
taking paracetamol or a nonsteroidal anti-inflammatory drug on an average of at least two days per week, for a continuous period of at least the one year before the clinical worsening of sensorineural hearing loss;
taking a cumulative total of at least 40 grams of aspirin, or having acute salicylate toxicity, within the 30 days before the clinical worsening of sensorineural hearing loss;
having a suppurative bacterial infection from the specified list of bacterial infections of the middle or inner ear, involving the affected side, within the 30 days before the clinical worsening of sensorineural hearing loss;
Note: specified list of bacterial infections is defined in the Schedule 1 - Dictionary.
having an infection with a virus from the specified list of viruses, within the 30 days before the clinical worsening of sensorineural hearing loss;
Note: specified list of viruses is defined in the Schedule 1 - Dictionary.
having viral labyrinthitis of the affected ear within the 30 days before the clinical worsening of sensorineural hearing loss;
having meningitis or encephalitis within the one year before the clinical worsening of sensorineural hearing loss;
having neurosyphilis before the clinical worsening of sensorineural hearing loss;
having tuberculosis of the meninges, middle ear or inner ear of the affected side, before the clinical worsening of sensorineural hearing loss;
having leprosy before the clinical worsening of sensorineural hearing loss;
having a disease from the specified list of bone diseases, affecting the petrous temporal bone or middle ear ossicles of the affected side, at the time of the clinical worsening of sensorineural hearing loss;
Note: specified list of bone diseases is defined in the Schedule 1 - Dictionary.
having osteoporosis at the time of the clinical worsening of sensorineural hearing loss;
having a disease from the specified list of autoimmune diseases at the time of the clinical worsening of sensorineural hearing loss;
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
having multiple sclerosis at the time of the clinical worsening of sensorineural hearing loss;
having diabetes mellitus at the time of the clinical worsening of sensorineural hearing loss;
having a disease from the specified list of haematological diseases at the time of the clinical worsening of sensorineural hearing loss;
Note: specified list of haematological diseases is defined in the Schedule 1 - Dictionary.
having a cerebrovascular accident within the three months before the clinical worsening of sensorineural hearing loss;
having a lesion interrupting the supply of blood to the cochlea of the affected ear at the time of the clinical worsening of sensorineural hearing loss;
Note: Examples of lesions interrupting the supply of blood to the cochlea include, but are not limited to, thrombosis, haemorrhage or vasospasm of the vertebro-basilar circulation, and intralabyrinthine haemorrhage or infarction.
having blunt trauma, penetrating trauma or surgery to the cochlea or auditory nerve of the affected side within the five years before the clinical worsening of sensorineural hearing loss;
Note: Examples of trauma include, but are not limited to, temporal bone fracture and basilar skull fracture.
having moderate to severe traumatic brain injury within the three months before the clinical worsening of sensorineural hearing loss;
having a benign or malignant neoplasm involving the affected auditory nerve or cochlea at the time of the clinical worsening of sensorineural hearing loss;
undergoing a course of therapeutic radiation for cancer, where the affected cochlea or auditory nerve was in the field of radiation, before the clinical worsening of sensorineural hearing loss;
inhaling, ingesting or having cutaneous contact with an agent from the specified list of chemical agents, for a cumulative period of at least 2 500 hours within a continuous period of five years, before the clinical worsening of sensorineural hearing loss, and where that exposure has ceased, the clinical worsening of sensorineural hearing loss has occurred within two years of cessation;
Note: specified list of chemical agents is defined in the Schedule 1 - Dictionary.
having:
a cobalt-containing metal-on-metal hip prosthesis; or
a serum cobalt concentration of at least 200 micrograms per litre;
for at least four weeks before the clinical worsening of sensorineural hearing loss;
smoking at least ten pack-years of cigarettes, or the equivalent thereof in other tobacco products, before the clinical worsening of sensorineural hearing loss, and where smoking has ceased, the clinical worsening of sensorineural hearing loss has occurred within five years of cessation;
Note: pack-years of cigarettes, or the equivalent thereof in other tobacco products is defined in the Schedule 1 - Dictionary.
being exposed to second-hand smoke:
for at least 2 500 hours before the clinical worsening of sensorineural hearing loss; and
where the first exposure to second-hand smoke commenced at least five years before the clinical worsening of sensorineural hearing loss; and
where the last exposure to second-hand smoke occurred within the two years before the clinical worsening of sensorineural hearing loss;
Note: being exposed to second-hand smoke is defined in the Schedule 1 - Dictionary.
consuming an average of at least 100 grams of alcohol per day for at least the four years before the clinical worsening of sensorineural hearing loss;
Note: Alcohol consumption is calculated utilising the Australian Standard of ten grams of alcohol per standard alcoholic drink.
being obese for at least five years within the ten years before the clinical worsening of sensorineural hearing loss;
Note: being obese is defined in the Schedule 1 - Dictionary.
having hypertension at the time of the clinical worsening of sensorineural hearing loss;
inability to obtain appropriate clinical management for sensorineural hearing loss.
Relationship to service
The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.
The factors set out in subsections 9(36) to 9(71) apply only to material contribution to, or aggravation of, sensorineural hearing loss where the person's sensorineural hearing loss was suffered or contracted before or during (but did not arise out of) the person's relevant service.
Factors referring to an injury or disease covered by another Statement of Principles
In this Statement of Principles:
if a factor referred to in section 9 applies in relation to a person; and
that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;
then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.
Schedule 1 - Dictionary
Note: See Section 6
1 Definitions
In this instrument:
being exposed to second-hand smoke means being in an enclosed space and inhaling smoke from burning tobacco products or smoke that has been exhaled by a person who is smoking.
being obese means having a Body Mass Index (BMI) of 30 or greater.
Note: BMI is also defined in the Schedule 1 - Dictionary.
BMI means W/H2 where:
W is the person's weight in kilograms; and
H is the person's height in metres.
chronic suppurative otitis media means a recurrent or continuous infective disorder of the middle ear characterised by perforation of the tympanic membrane and aural discharge.
dB(A) means the sound pressure level in decibels measured by a sound level meter using a type A electronic filter.
dB(C) means the sound pressure level in decibels measured by a sound level meter using a type C electronic filter. The type C filter is used to measure peak or impact sound pressure levels.
hyperviscosity syndrome means a disorder causing an increased viscosity of the blood.
Note: Examples of disorders causing an increased viscosity of the blood include, but are not limited to, polycythaemia and Waldenstrom macroglobulinaemia.
MRCA means the Military Rehabilitation and Compensation Act 2004.
ototopical medication as specified means ear drops containing one or more of the following agents:
(a) Burow's solution (5% aluminium subacetate);
(b) aminoglycosides;
(c) chloramphenicol;
(d) chlorhexidine; or
(e) ethanol.
pack-years of cigarettes, or the equivalent thereof in other tobacco products means a calculation of consumption where one pack-year of cigarettes equals 20 tailor-made cigarettes per day for a period of one calendar year, or 7 300 cigarettes. One tailor-made cigarette approximates one gram of tobacco or one gram of cigar or pipe tobacco by weight. One pack-year of tailor-made cigarettes equates to 7.3 kilograms of smoking tobacco by weight. Tobacco products mean cigarettes, pipe tobacco or cigars, smoked alone or in any combination.
relevant service means:
(a) operational service under the VEA;
(b) peacekeeping service under the VEA;
(c) hazardous service under the VEA;
(d) British nuclear test defence service under the VEA;
(e) warlike service under the MRCA; or
(f) non-warlike service under the MRCA.
Note: MRCA and VEA are also defined in the Schedule 1 - Dictionary.
sensorineural hearing loss—see subsection 7(2).
specified list of autoimmune diseases means:
(a) antiphospholipid antibody syndrome;
(b) Behcet disease;
(c) Cogan syndrome;
(d) eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome);
(e) giant cell arteritis;
(f) granulomatosis with polyangiitis (Wegener granulomatosis);
Note: chronic suppurative otitis media and suppurative labyrinthitis are also defined in the Schedule 1 - Dictionary.
specified list of bone diseases means:
(a) acromegaly;
(b) otosclerosis; or
(c) Paget's disease of bone.
specified list of chemical agents means:
(a) allyl benzene;
(b) cadmium;
(c) carbon disulphide;
(d) carbon monoxide;
(e) dimethylacetamide;
(f) epoxy adhesives;
(g) ethyl benzene;
(h) lead or fumes containing lead;
(i) manganese or fumes containing manganese;
(j) mercury;
(k) methyl ethyl ketone (MEK);
(l) n-hexane;
(m) n-propylbenzene;
(n) xylene;
(o) styrene;
(p) toluene; or
(q) trichloroethylene.
specified list of drugs means:
(a) α-difluoromethylornithine (eflornithine);
(b) 2-hydroxypropyl-b-cyclodextrin (HPbCD);
(c) aminoglycosides;
(d) carboplatin;
(e) cisplatin;
(f) erlotinib;
(g) 5-fluorouracil (5-FU);
(h) gabapentin;
(i) imatinib;
(j) loop diuretics;
(k) macrolide antibiotics;
(l) misonadazole;
(m) nitrogen mustard compounds;
(n) opioids;
(o) oxaliplatin;
(p) phosphodiesterase 5 inhibitors;
(q) propylthiouracil;
(r) quinine and quinine derivatives, including mefloquine;
(s) tetracyclines;
(t) valproic acid;
(u) vancomycin;
(v) vigabatrin; or
(w) vinca alkaloids.
specified list of haematological diseases means:
(a) aplastic anaemia;
(b) hyperviscosity syndrome;
(c) Langerhan cell histiocytosis;
(d) leukaemia;
(e) myelodysplastic syndrome; or
(f) sickle-cell disorder.
Note: hyperviscosity syndrome is also defined in the Schedule 1 - Dictionary.
specified list of viruses means:
(a) cytomegalovirus;
(b) hepatitis B virus;
(c) hepatitis C virus;
(d) herpes simplex virus types 1 or 2;
(e) human immunodeficiency virus;
(f) Lassa virus;
(g) measles virus;
(h) mumps virus; or
(i) varicella-zoster virus infection of the geniculate ganglion on the affected side.
Note: Varicella-zoster virus infection of the geniculate ganglion is also known as herpes zoster oticus or Ramsay-Hunt syndrome.
suppurative labyrinthitis means inflammation of the inner ear characterised by the presence of pus.
terminal event means the proximate or ultimate cause of death and includes the following:
(a) pneumonia;
(b) respiratory failure;
(c) cardiac arrest;
(d) circulatory failure; or
(e) cessation of brain function.
time-weighted average (TWA) with a 3-dB exchange rate means the time-weighted average noise exposure level calculated according to the following formulae and shown in the table:
TWA = 10.0 x Log(D/100) + 85
where D = daily dose; and
D = [C1/T1 + C2/T2 + …..+ Cn/Tn] x 100
where Cn = total time of exposure at a specified noise level; and
Tn = exposure duration for which noise at this level becomes hazardous.
Source: National Institute of Occupational Safety and Health 1998 Guidelines Publication No. 98-126
VEA means the Veterans' Entitlements Act 1986.
Note: Endnotes
Note: Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.
If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.
Note: Endnote 2—Abbreviation key
o = order(s)
ad = added or inserted
Ord = Ordinance
am = amended
orig = original
amdt = amendment
par = paragraph(s)/subparagraph(s)
c = clause(s)
/sub‑subparagraph(s)
C[x] = Compilation No. x
pres = present
Ch = Chapter(s)
prev = previous
def = definition(s)
(prev…) = previously
Dict = Dictionary
Pt = Part(s)
disallowed = disallowed by Parliament
r = regulation(s)/rule(s)
Div = Division(s)
exp = expires/expired or ceases/ceased to have
reloc = relocated
effect
renum = renumbered
F = Federal Register of Legislation
rep = repealed
gaz = gazette
rs = repealed and substituted
LA = Legislation Act 2003
s = section(s)/subsection(s)
LIA = Legislative Instruments Act 2003
Sch = Schedule(s)
(md) = misdescribed amendment can be given
Sdiv = Subdivision(s)
effect
SLI = Select Legislative Instrument
(md not incorp) = misdescribed amendment
SR = Statutory Rules
cannot be given effect
Sub‑Ch = Sub‑Chapter(s)
mod = modified/modification
SubPt = Subpart(s)
No. = Number(s)
underlining = whole or part not
commenced or to be commenced
Note: Endnote 3—Legislation history
Name
Registration
Commencement
Application, saving and transitional provisions
Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 98 of 2019)
21 October 2019F2019L01360
18 November 2019
Amendment Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 55 of 2022)
3 May 2022F2022L00672
30 May 2022
Amendment Statement of Principles concerning sensorineural hearing loss (Reasonable Hypothesis) (No. 75 of 2025)
26 August 2025F2025L00977
22 September 2025
Note: Endnote 4—Amendment history
Provision affected
How affected
Section 2……………….
rep LA s 48D
Section 4……………….
rep LA s 48C
Schedule 1 – Dictionary – specified list of chemical agents…...….